FDA grants EUA to Pfizer’s anti - COVID pill Paxlovid | Inquirer News
Close  

FDA grants EUA to Pfizer’s anti – COVID pill Paxlovid

By: - Reporter / @DYGalvezINQ
/ 11:59 AM March 11, 2022
FILE PHOTO: Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS

Paxlovid, a Pfizer’s coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. (Pfizer/Handout via REUTERS)

MANILA, Philippines — The Food and Drug Administration (FDA) has granted an emergency use authorization for Pfizer’s antiviral COVID-19 pill Paxlovid, officer-in-charge Oscar Gutierrez said Friday.

Apart from Paxlovid, the FDA also granted an EUA for another brand of another COVID-19 treatment pill molnupiravir.

ADVERTISEMENT

“Masaya kong binabalita na naaprubahan na namin ang paxlovid kahapon at mayroong nadagdag na isang mulnopriavir na gamot,” he said in a Laging Handa briefing.

(I am happy to announce that we have approved the Paxlovid yesterday and another brand of molnupiravir.)

FEATURED STORIES

Gutierrez said the molnupiravir brand is called Molenzavir, which is manufactured in Bangladesh.

The FDA earlier granted a compassionate use permit for a generic version of Paxlovid called Bexovid.

In December last year, the FDA approved an EUA for molnupiravir. The agency has approved six other brands of the anti-COVID pill since then.

gsg/MUF

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: covid-19 pill, EUA, FDA, Paxlovid
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.